Crispr Therapeutics AG (CRSP) stock has risen 22.24% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 62 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 76. CRSP's rank also includes a fundamental score of 55. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 72. This means analysts expect the stock to increase 46.22% over the next 12 months. The long-term technical score for CRSP is 54.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock is higher by 0.09% while the S&P 500 is unchanged 0% as of 11:20 AM on Friday, May 1. CRSP has risen $0.04 from the previous closing price of $49.20 on volume of 326,369 shares. Over the past year the S&P 500 is lower by -0.17% while CRSP has risen 22.24%. CRSP earned $0.75 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 65.84.